Snapshot from Sep 23, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory approval

FDA Approves Guardant360 CDx for Breast Cancer

Analysis based on 9 articles · First reported Sep 04, 2026 · Last updated Sep 06, 2026

Sentiment
60
Attention
4
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The approval strengthens Guardant Health's position in precision oncology and expands the market for its liquid biopsy platform, likely boosting revenue and investor confidence. AstraZeneca benefits from a broader patient population eligible for ETCAMAH, potentially increasing drug sales and reinforcing its oncology portfolio.

Biotechnology Pharmaceuticals Diagnostics

The U.S. United States — Food and Drug Administration approved Guardant Health's Guardant360 CDx as a companion diagnostic to identify patients with HR-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations before radiographic progression, who may benefit from treatment with AstraZeneca's ETCAMAH (camizestrant). This is the first FDA-approved liquid biopsy CDx for longitudinal testing in breast cancer, enabling adaptive cancer management through pre-radiographic ctDNA testing. The approval is based on data from the pivotal SERENA-6 trial, which showed a 56% reduction in risk of progression or death for patients switched to camizestrant upon ESR1 mutation detection. This marks the 29th CDx indication for Guardant360 CDx globally.

80 Guardant Health announced FDA approval
stock
Guardant Health received FDA approval for its Guardant360 CDx as a companion diagnostic for ESR1-mutated breast cancer, its 29th CDx indication. This expands its clinical utility and market reach, likely enhancing revenue and competitive position.
Importance 100.0 Sentiment 80.0
stock
AstraZeneca's drug ETCAMAH (camizestrant) is now paired with a companion diagnostic, enabling identification of ESR1-mutated breast cancer patients who may benefit. This approval could expand the drug's eligible patient population and support its commercial success.
Importance 90.0 Sentiment 70.0
govactor
The FDA granted approval, validating the clinical utility of liquid biopsy companion diagnostics and supporting the shift toward adaptive cancer management. This regulatory action may influence future diagnostic approvals.
Importance 80.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.